Atypical antipsychotics: New etiology in type 2 diabetes mellitus;Antipsicóticos atípicos: Una nueva etiología en la diabetes mellitus tipo 2

Medicina Clinica

Volumn 124, Issue 9, 2005, Pages 341-343

  Flores Meneses, Lilian ^a   Sanmartí Sala, Anna ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ATHEROGENESIS; EDITORIAL; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PSYCHOSIS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 17644411460     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072424     Document Type: Editorial

References (36)

1. Casey D. Barriers to progress: the impact of tolerability problems. Int Clin Psychopharmacol. 2001;16(Suppl 1):15-19.
2. Allison D, Casey D. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatric. 2001;62(Suppl 7):22-31.
3. Sussman N. Review of atypical antipsychotic and weight gain. J Clin Psychiatric. 2001;62(Suppl 23):5-12.
4. Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-96.
5. Basson B, Kinon B, Taylor C, Szymanski K, Gilmore J, Tollefson G. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry. 2001;62:231-8.
6. Czobor P, Volavka J, Sheitman B, Lindenmayer J, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22:244-51.
7. Kurzthaler I, Fleeischhacker W. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62(Suppl 7):32-7.
8. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903-12.
9. Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004;65:715-20.
10. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci. 2002;22:6742-6.
11. Baptista T, Kin N, Beaulieu S, De Baptista E. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35:205-19.
12. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124:978-82.
13. Langfeldt G. The insulin tolerance test in mental disorders. Acta Psychiatry Scand. 1952;80:189-200.
14. Ryan M, Collins P, Thakore J. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry. 2003;160:284-9.
15. Allison D, Fontaine K, Heo M, Mentore J, Cappelleri J, Chandler L, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-20.
16. Elmslie J, Silverstone J, Mann J, Williams S, Romans S. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;61:179-84.
17. Mukherjee S, Schnur D, Reddy R. Family history of type 2 diabetes in schizophrenic patients [letter]. Lancet. 1989;1:495.
18. Kamran A, Doraiswamy P, Jane J, Hammett E, Dunn L. Severe hyperglycaemia associated with high doses of clozapine [letter]. Am J Psychiatry. 1994;151:1395.
19. Colli A, Cocciolo M, Francobandiera F, Rogantin F, Cattalini N. Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care. 1999;22:176-7.
20. Goldstein L, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey G, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;4:438-43.
21. Sernyak M, Douglas D, Alarcon R, Losonczy M, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-6.
22. Newcomer J, Haupt D, Fucetola R, Melson A, Schweiger J, Cooper B, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-45.
23. Koro C, Redder D, L'Italien G, Weiss S, Magder L, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243-7.
24. Gianfrancesco F, White R, Wang R, Nasrallah H. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328-35.
25. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56:164-70.
26. Lindenmayer J, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotic. Am J Psychiatry. 2003;160:290-6.
27. Lieberman J, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drug in treatment-naive first episode schizophrenia: a 52 week randomised trial of clozapine vs. chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003.
28. Lean M, Pajonk F. Patients on atypical antipsychotic drugs. Diabetes Care. 2003;26:1597-605.
29. Prior T, Chue P. Oral glucose challenge test abnormalities with atypical antipsychotic use. Schizophr Res. 199;36:1-3.
30. Newcomer J, Haupt D, Melson A. Insulin resistance measured with euglycemic clamps during antipsychotic treatment in schizophrenia [abstract]. Biol Psychiatry. 2002;51:25S.
31. Bromel T, Blum W, Ziegler A, Schulz E, Bender M, Fleischhaker C, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry. 1998;3:76-80.
32. Melkersson K, Hulting A, Brismar K. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. Clin Psychiatry. 2000;61:742-9.
33. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
34. Schizophrenia and Diabetes 2003. Expert Consensus Meeting. Br J Psychiatr. 2004;187(Suppl 47):112-4.
35. Gaulin B, Markowitz J, Caley C, Nesbitt L, Dufresne R. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156:1270-2.
36. Esmatjes Mompó E, Flores Meneses L. Importancia de las alteraciones endocrinas producidas por antipsicóticos. Actas Esp Psiquiatr. 2002;30:29-34.